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_______________________________________________  13 
Abstract 14 
Metals such as mercury, arsenic, copper and silver have been used in various forms 15 
as antimicrobials for thousands of years, with until recently, little understanding of 16 
their mode of action. The discovery of antibiotics and new organic antimicrobial 17 
compounds during the twentieth century saw a general decline in the clinical use of 18 
antimicrobial metal compounds, with the exception of the rediscovery of the use of 19 
silver for burns treatments, and niche uses for other metal compounds. Antibiotics 20 
and new antimicrobials were regarded as being safer to the patient and more 21 
effective than the metal-based compounds they supplanted.  22 
Bacterial metal ion resistances were first discovered in the second half of the 23 
twentieth century. The detailed mechanisms of resistance have now been 24 
characterized in a wide range of bacteria. As the use of antimicrobial metals is 25 
limited, it is legitimate to ask: are antimicrobial metal resistances in pathogenic and 26 
commensal bacteria important now? This review will detail the new, rediscovered 27 
and ‘never went away’ uses of antimicrobial metals; will examine the prevalence 28 
and linkage of antimicrobial metal resistance genes to other antimicrobial resistance 29 
genes; and will examine the evidence of horizontal transfer of these genes between 30 
bacteria. Finally, it will discuss the possible implications of the widespread 31 
dissemination of these resistances on re-emergent uses of antimicrobial metals and 32 
how this could impact upon the antibiotic resistance problem. 33 
_______________________________________________ 34 
35 
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Introduction  36 
Metals and metalloids have had a long empirical history of human usage in 37 
medicine or agriculture, as reviewed below; despite problems of host toxicity, or 38 
doubts about their efficacy.  Even now, a few toxic metal(loid) compounds are still 39 
first-line drugs or preferred choice chemotherapeutics or antimicrobials; although 40 
the use of most of the previously popular antimicrobial metal(loid)s such as 41 
mercury and arsenic/antimony compounds has been reduced or phased out in the 42 
past fifty or so years. Other metals such as silver and copper still have limited uses 43 
in agriculture and medicine, but are increasingly being included in consumer 44 
products, from clothing to computer keyboards, and are being promoted as useful 45 
additions to our arsenal of antimicrobials. Against this background of their current 46 
usage, it is reasonable to ask: What is the relevance of antimicrobial metals, 47 
and bacterial resistances to them to medical microbiology in the 21
st
 48 
century?  49 
Any attempt to address this question must be set against the backdrop of widely 50 
known problems and opportunities: We are faced with new and emerging 51 
opportunistic nosocomial and community acquired pathogens; and increasing 52 
epidemic and pandemic multidrug resistant (MDR) pathogens. There is a 53 
recognition that the antibiotic discovery pipeline has not delivered significant 54 
quantities of new antibiotics in the past few decades, and new formulations and 55 
uses for antimicrobial metals as weapons in the antimicrobial armoury are being 56 
proposed (Annual Report of the Chief Medical Officer, 2011; Lemire et al., 2013). 57 
The recent recommendation by the Chief Medical Officer that antimicrobial 58 
resistance should be added into the UK National Security Risk Assessment 59 
(https://www.gov.uk/government/news/uk-antimicrobial-resistance-strategy-60 
published--2 ) provides a timely backdrop to a discussion about resistance to 61 
antimicrobials that have been in clinical, non-clinical, and agricultural use for far 62 
longer than antibiotics have been.   63 
 64 
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This review will briefly discuss a wide range of antimicrobial metals but will 65 
concentrate on a limited number of the historically most important and most widely 66 
used (copper (Cu), silver (Ag), mercury (Hg), arsenic (As) and antimony (Sb)), and 67 
the microbial resistances to them. In this article we examine the past and current 68 
uses of antimicrobial metals, and the importance of the genetic legacy and 69 
dissemination of bacterial resistance to antimicrobial metals in bacteria.  In 70 
particular we will discuss the genetic elements carrying multiple antimicrobial 71 
resistances, both to metals and antibiotics.  72 
 73 
Metals in medicine and agriculture - past and present uses 74 
Arguably the most important uses of metals and metalloids in medicine and 75 
agriculture have been as biocides and antimicrobials.   76 
Probably the most commonly used toxic metals or metalloids in medicine and 77 
agriculture have been: mercury (Hg), copper (Cu), silver (Ag), arsenic (As) and 78 
antimony (Sb), and will be dealt with in detail in this review. Other inorganic or 79 
organic metal compounds such as lead  (Pb) (Lenihan 1988, Trotter, 1990), tin (Sn) 80 
(Barnes and Stoner, 1959; Cooney and Wuertz, 1989), zinc (Zn) (Aarestrup and 81 
Haasman 2004), bismuth (Bi) (Mahony et al., 1999; Yang and Sun 2007; Ge and 82 
Sun 2007), gold (Au) (Novelli et al., 1999; Ray et al., 2007), cerium (Ce) (Garner 83 
and Heppell 2005), palladium (Pd) (Ray et al., 2007), tellurite (Te) (Taylor 1999), 84 
thallium (Tl) (Kazantzis, 2000) and gallium (Ga) (Chitambar, 2010) have also been 85 
investigated or had limited use as antimicrobials. Of these less heavily used 86 
antimicrobial metals, zinc, bismuth, and tin are still in common use in consumer 87 
products. Although zinc is an essential element required for life and is found in 88 
many enzymes, zinc ions can be effective as antimicrobials even at low 89 
concentration.  Zinc compounds have been described since at least Roman times as 90 
an ancient ingredient in eye disease treatment, and zinc tablets were found in a 91 
small medical container dating back to 140-130BC retrieved from a Roman 92 
shipwreck (Giachi et al., 2013). Current  use of some of these metals include the 93 
use of zinc oxide as a mild antiseptic most often used topically to protect against 94 
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diaper/nappy rash or skin irritation.  Zinc compounds are also found in toothpastes 95 
(Zinc chloride) and shampoos (zinc pyrithione), and used as a growth 96 
promoter/treatment for postweaning diarrhea  in animal feeds (Hasman et al., 97 
2006). Stannous fluoride is used in toothpastes, and bismuth subsalicylate is used 98 
to treat diarrhea and other digestive system disturbances (Lemire et al., 2013). 99 
In addition, compounds containing gold (Au), platinum (Pt), palladium (Pd), 100 
vanadium (V), rhodium (Rh), titanium (Ti), iridium (Ir) and other rare metals have 101 
been used recently in medical diagnostics or imaging; as radiotherapeutics; or as 102 
anti-arthritis and anti-cancer therapeutics (Abrams and Murrer 1993; Guo and 103 
Sadler, 1999; Xin Zhang, and Lippard, 2003; Desoize, 2004).  104 
The medical and agricultural uses of mercury, copper, silver, arsenic and antimony 105 
as antimicrobials are discussed in detail below.  106 
 107 
Mercury 108 
This element has no known positive role in cellular function and the toxicity to 109 
humans of mercury and inorganic mercury compounds have been known since the 110 
First Century AD (Lenihan, 1988). The very high levels of toxicity of ethyl and 111 
methyl- mercury compounds to humans have been known since they were first 112 
synthesized in the laboratory in the mid-19
th
 Century, when two laboratory 113 
assistants died several weeks after helping to synthesize dimethylmercury. Even so, 114 
organic and inorganic mercury compounds have been widely used in agriculture and 115 
medicine. Organic compounds containing mercury were used in agriculture to 116 
control plant diseases from the late nineteenth century until the 1970’s, with aryl- , 117 
aloxyl-, and alkyl- organomercurials becoming widely used in the 1950’s,  118 
particularly as antifungal seed dressings, but also as pesticides and fungicidal 119 
sprays (Huisingh 1974). Antifungal methylmercury cereal seed treatments resulted 120 
in death when treated wheat was consumed by humans in Guatemala and Iraq 121 
(briefly summarized in Hobman and Silver, 2007), and mortality and reproductive 122 
failure of seed eating birds has also been linked to organomercurial seed dressings. 123 
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Use of organomercurial seed dressings was discontinued because of these 124 
problems.  125 
Inorganic mercury compounds have been used in a variety of medicines: as a 126 
laxative, diuretic, and antidepressant, but also to treat sexually transmitted 127 
diseases, skin disorders, and as a topical antimicrobial since at least the 15
th
 128 
century, when inorganic salts of mercury or mercury metal were primarily used to 129 
treat syphilis- either as an ointment, or fumigant (Hobman and Brown 1997). The 130 
effects of the treatment were only slightly less unpleasant than the disease, and 131 
probably futile.  Mercury metal, (Hg, hydrargyrum); Mercuric chloride (corrosive 132 
sublimate; HgCl
2
), mercurous chloride (calomel; Hg
2
Cl
2
), and mercury nitrate 133 
(Hg(NO
3
)
2
) have been used as the active ingredient in many medical treatments. 134 
Included in these uses was the 19
th
 century universal remedy, the blue mass (or 135 
blue pill) used for treating everything from tuberculosis to parasites, but most 136 
famously in the Royal Navy of the Napoleonic Wars for treating constipation, in 137 
conjunction with the black draught.  In hindsight, it seems strange that although 138 
the toxic effects of mercury on humans had been known since antiquity, mercurous 139 
chloride was commonly used in baby teething powders in the Anglo-Saxon World 140 
and in “Wurmschokolade” in continental Europe in the early twentieth century. 141 
Unfortunately this use of inorganic mercury compounds in these medicines led to 142 
Pink disease (acrodynia) in children (Black 1999). The known toxicity of mercuric 143 
ion compounds (particularly mercuric chloride) and doubts about their efficacy 144 
meant that mercuric chloride in the primary treatment of syphilis was replaced by 145 
Salvarsan
®
 (arsphenamine)  in the early 20
th
 century, making redundant the 146 
aphorism “a night with Venus, a lifetime with mercury” (although mercury or 147 
bismuth was sometimes still used as an adjunct  treatment to Salvarsan). After 148 
World War II antibiotics became the standard treatment for syphilis, but mercury 149 
use continued in diuretics (Hall, 1970) antiseptics and in organomercurial 150 
antimicrobial compounds in hospitals in the U.K. and America until the early 1970s 151 
(Porter et al., 1982) and until the 1990’s in over-the-counter antiseptics and 152 
ointments (Golden eye ointment used to contain 1-3% mercuric oxide). 153 
Ammoniated mercury (NH
4
HgCl) was being used to treat psoriasis, ringworm and 154 
impetigo in the 1970’s (Foye, 1977) and may still be available in some countries. A 155 
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variety of organomercurial antimicrobial and antifungal agents such as nitromersol, 156 
mercurophen, phenylmercuric borate, phenylmercuric nitrate,  and ortho-157 
hydroxyphenylmercuric chloride have been used as disinfectants, preservatives and 158 
antiseptics. Even in 2014 over the counter 0.5% v/v chloramphenicol eyedrops 159 
bought in the UK contain 0.002% w/v phenylmercuric nitrate as a preservative. 160 
One of the most well-known of the organomercurial preservatives  is thimerosal/ 161 
thiomersal, (Merthiolate - sodium ethylmercurithiosalicylate) which has been 162 
widely used as a topical antiseptic or preservative, and is still in use in the UK as a 163 
preservative. 164 
Mercury containing antimicrobial usage is in decline, and is likely to be eliminated. 165 
The use of thiomersal/thimerosal as a vaccine preservative has been subject to 166 
vigorous debate, and controversy, and it has been banned in some countries. Other 167 
mercury containing disinfectants include merbromin (Mercurochrome) and 168 
nitromersol that have been superseded or withdrawn in the U.S. or Europe.  169 
The largest current use of mercury in a healthcare associated role is in dental 170 
amalgam, which typically contains 43-54% Hg, 20-35% Ag, 15% Sn, 10% Cu, 2% 171 
Zn, depending on formulation (Franke 2007). There has been debate about the 172 
safety of mercury amalgam fillings and whether use of them has negative effects on 173 
human health or may select for mercuric ion resistant bacteria, although a recent 174 
ruling by the U.S. Food and Drugs Administration stated that dental amalgam was 175 
safe. In the UK dental amalgam can be used unrestricted, but there are limitations 176 
in its use in some other European countries, and bans in place in the Nordic 177 
countries. 178 
 179 
Copper 180 
Copper is an essential metal to aerobic forms of life, being involved in donating or 181 
accepting electrons in redox active enzymes, or in the electron transport chain 182 
(Solioz et al., 2010). Copper is also toxic to prokaryotes and eukaryotes at higher 183 
cellular concentrations (Gaetke and Chow 2003), and copper (and zinc) 184 
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involvement  in phagosomal killing of bacteria engulfed by macrophages  is being 185 
recognized as an important defence mechanism (see German et al., 2013) . 186 
Copper compounds are used as wood preservatives, in antifouling paints, and as 187 
molluscicides (Borkow and Gabbay, 2009). In agriculture, copper compounds have 188 
been used as an antimicrobial, algicide, pesticide, and antifungal agent and as an 189 
animal feed additive. Copper sulphate solutions were used as an antifungal 190 
treatment of seed grains in the 18
th
 century.   In the late 19
th
 century Bordeaux 191 
mixture (copper sulphate and calcium hydroxide) and Burgundy mixture (copper 192 
sulphate and sodium carbonate) were widely used to control mildew on grape vines 193 
and to control fungal and bacterial disease of seeds or plants (Bremner, 1998). 194 
These inorganic antifungal agents are still widely used in plant protection, even in 195 
“Organic” agriculture. Copper sulphate is allowed alongside zinc chloride, oxide or 196 
sulphate as an additive in animal and poultry feed.  In the European Union copper 197 
sulphate can be added at up to 250 ppm in piglet feed, but also at 25 ppm in feed 198 
for slaughter weight pigs, 20 ppm in broiler chickens and 2 ppm in calves as a 199 
growth promoter (Barber et al., 1955) and for postweaning control of diarrhoea 200 
(Hasman et al 2006, Sapkota et al., 2007). Alongside copper sulphate, zinc oxide 201 
can be added at up to 2500ppm in piglet feed to control post-weaning diarrhoea. 202 
The medical uses of copper and inorganic salts of copper go back at least 4000 203 
years with copper or copper compounds being used as astringents, antiseptics and 204 
antifungals, to treat wounds, and to purify and sterilize drinking water, and in 205 
contraceptive intrauterine devices, (see Borkow and Gabbay, 2009). Inorganic and 206 
organic copper compounds have been used to treat a variety of skin diseases, 207 
syphilis, TB and anaemia amongst other maladies (Grass et al., 2011). There is also 208 
interest in copper containing wound/ulcer dressings that have been trialled and 209 
reported to be effective (Borkow and Gabbay 2009; Borkow et al., 2010). Various 210 
laboratory and clinical studies have confirmed that solid copper/ copper alloy 211 
surfaces promote rapid killing of Gram-negative and Gram-positive bacteria. Most 212 
recently, the use of copper antimicrobial solid surfaces to reduce microbial 213 
contamination and transmission of hospital-acquired infections has progressed to 214 
clinical trials, with the installation of copper containing surfaces and fixtures in 215 
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wards and clinics. Reduction in microbial numbers, and therefore cross 216 
contamination has been seen (Casey et al., 2010, Marais et al., 2010, Mikolay et 217 
al., 2010). Copper usage in consumer items is perhaps less common than silver, 218 
but includes the use of copper oxide impregnated bedding to control house dust 219 
mites and socks to treat Athlete’s foot (Borkow and Gabbay 2009). Antimicrobial 220 
copper surfaces and products may also appear in products available to the domestic 221 
market, now that the U.S. EPA has registered copper and copper alloys as public 222 
health antimicrobial products. 223 
 224 
Silver 225 
There is no known beneficial role for silver in metabolism, and it is highly toxic to 226 
bacteria (Nies 1999). We have not been able to find any evidence in the literature 227 
for the use of silver compounds as antimicrobials in agriculture, except for the use 228 
of silver iodide (AgI) in cloud seeding,  but the first use of silver as an antibacterial 229 
is reported to have occurred over 2000 years ago in drinking water containers 230 
(Silver, 2006), and silver is still widely used in water filters and in other treatments 231 
for potable water, or as an algicide for swimming pools.  232 
Medically, silver nitrate, (lunar caustic; AgNO
3
) was used empirically to treat ulcers 233 
and burns in the 17
th
 -19
th
 centuries, and as a cauterizing agent.  It was understood 234 
in the late 19
th
 century that metallic silver and silver nitrate had antibacterial 235 
properties, with metallic silver foil and silver nitrate solutions being used to treat 236 
fresh and infected burns and wounds, or silver wire being used to suture surgical 237 
wounds. Following the success of arsphenamine (Salvarsan
®
) in combination with 238 
mercury or bismuth salts as a treatment for syphilis (see above and below), Silver 239 
arsphenamine (Neo silvol
®
) by injection into the spine was used in the 1920’s as 240 
treatment for neurosyphilis. 2% silver nitrate solution has also been used in 241 
treating warts and eye infections and as a prophylactic against gonorrhoeal 242 
ophthalmia neonatorum (Klasen 2000a), and silver metal is a major component of 243 
dental amalgam. 244 
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The introduction of sulphonamide  in the 1930s and antibiotics in the 1940s appears 245 
to have led to an almost complete disappearance of interest in the use of silver and 246 
silver salts in burn and other treatments, until the 1960’s, when Moyer and co-247 
workers looked for antimicrobial agents that prevented invasive burns infections 248 
(Moyer et al., 1965). Combinations of 0.5% silver nitrate and Sulphamylon
®
 249 
became popular burns treatments in the mid 1960’s and silver sulphadiazine 250 
(Flammazine
®
, Silvadene
®
)(SSD) was developed shortly after by Fox and co-251 
workers as a burn treatment. SSD is a common treatment for serious burns 252 
(reviewed in Klasen 2000b). More recently, silver impregnated dressings and 253 
antimicrobial coatings have been used in infection management, stimulation of 254 
healing, wound management and treatment of infected wounds, and as 255 
antimicrobial coatings in catheters and endotracheal breathing tubes (Silver, 2003; 256 
Silver et al., 2006; Chopra 2007, Mijnendonkx et al., 2013).  257 
Silver is generally viewed as a benign metal, and the only widely reported negative 258 
health effects of silver to humans have been eschar formation on burns treated by 259 
silver, staining or destruction of skin cells when silver nitrate is directly applied for 260 
treatment of warts, sometimes elevated silver levels in blood, and the rare argyria 261 
and argyrosis in people who self-medicate colloidal silver solutions (Silver 2006). 262 
There is some concern about silver and silver nanoparticle toxicity to other 263 
(particularly aquatic) organisms (Panyala et al., 2008; Chaloupka et al., 2010), 264 
initially based upon the premise that silver nanoparticles were new materials that 265 
had not been encountered in nature before, with counter arguments that silver 266 
nanoparticles have been produced in colloidal silver preparations for over a century 267 
and the majority of approved silver biocides release nanosilver (Nowack et al., 268 
2011). Copper/silver ionization treatments have been used in hospital water 269 
supplies and the International Space Station has silver coated water tanks (Van 270 
Houdt et al 2012; Mijnendonkx et al., 2013) 271 
One quite noticeable increase in the use of antimicrobial metal products, is the use 272 
of silver in consumer and “lifestyle” products. In the past 20 years or so silver-273 
containing plasters, clothes, water filters, personal hygiene and consumer products 274 
have appeared worldwide (Silver, 2003; Silver and Phung, 2006; Edwards-Jones, 275 
  11 
2009, Minendonkx et al., 2013), and the use of antimicrobial silver nanoparticles in 276 
products is also growing (Chaloupka et al., 2010) including examples where they 277 
have been integrated into household items such as computer keyboards, washing 278 
machine drums, air conditioners and refrigerators.  279 
 280 
Arsenic 281 
Arsenic has been used for at least 2000 years as a medicine, cosmetic, tonic, or as 282 
a poison. Arsenic trioxide (As
2
O
3
), (also known as Ratsbane, Inheritance powder or 283 
poudre de succession) is colourless and flavourless when put in food or drink and 284 
was popular as a rat poison. Prior to the advent of sensitive and accurate chemical 285 
tests for arsenic, such as the Marsh test, it is believed that arsenic trioxide was also 286 
a popular choice for poisoning people, especially as the symptoms of arsenic 287 
poisoning somewhat  resemble cholera, and post-mortem toxicology was 288 
weak/non-existent. Organic arsenic compounds such as Lewisite (2-289 
chloroethenylarsonous dichloride) and Adamsite (Dibenzo-1-chloro-1,4-arsenine) as 290 
well as a range of other organoarsenic halides have also been developed as 291 
chemical warfare agents. 292 
Agricultural and non-medical uses of arsenic compounds have included arsenical 293 
wood preservatives (particularly chromated copper arsenate-CCA), herbicides, 294 
rodenticides, defoliants (Agent Blue used in the Vietnam war was a mixture of 295 
dimethylarsenic acid and its sodium salt (Cooksey 2012)), and fungicides.  Prior to 296 
the introduction of organic pesticides; arsenic compounds such as lead arsenate 297 
and Paris green (Copper (II) acetoarsenite) were used as a rodenticides and 298 
insecticides. Copper-arsenic and lead-arsenic compounds were used widely as 299 
insecticides in orchards from the 1930s to the 1980s, and calcium arsenate and 300 
dimethylarsenate were widely used as pesticides (Oremland and Stolz, 2003). 301 
Organic arsenic compounds: Carbarsone (4-Carbamoylaminophenylarsonic acid), 302 
Nitarsone (4-nitrophenylarsonic acid), and Roxarsone (3-nitro-4-303 
hydroxyphenylarsonic acid) have been used as feed additives for poultry in the 304 
United States acting as growth promoters and in controlling coccilobacillosis disease 305 
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(Jones 2007). Only very recently (June 2011), has the U.S. FDA announced the 306 
voluntary suspension of the sale of Roxarsone due to the presence of inorganic 307 
arsenic residues in chicken meat from chickens fed on Roxarsone supplemented 308 
feeds.  309 
In medicine, arsenic oxide (white arsenic:  As
2
O
3
), arsenic sulphide (red realgar: 310 
As
4
S
4
), and arsenic trisulphide (yellow orpiment: As
2
S
3
) have variously been used 311 
as antispasmodics, sedatives, hematinics, for treating skin disorders, as eye and 312 
cancer treatments, in the treatment of trichomoniasis, malaria, ulcers, and syphilis 313 
as well as a wide range of other ailments (Liu et al., 2008). Arsenic compounds 314 
were so widely used in the 18
th
 century that it became known as the “Therapeutic 315 
Mule” (Przygoda et al., 2001). Fowler’s solution was a very well-known inorganic 316 
arsenical medicine (1% arsenic trioxide in potassium carbonate with tincture of 317 
lavender) which was still being used even after World War II as a tonic and 318 
treatment for malaria, syphilis and chorea (Przygoda et al., 2001).  319 
In the early part of the 20th century the organic arsenic compound Salvarsan, (‘the 320 
arsenic that saves') was probably the best-known arsenic compound used in 321 
medicine. Salvarsan (compound 606, arsphenamine) and subsequently 322 
Neosalvarsan
®
 (compound 914, neoarsphenamine) were developed by Ehrlich and 323 
co-workers primarily to effectively treat syphilis. Later, it was realized that once 324 
administered by injection, arsphenamine oxidized to oxophenarsine (later given the 325 
trade name Mapharsen
®
) that was subsequently used as the drug of choice in 326 
syphilis treatment until the introduction of penicillin (Bosch and Rosich, 2008). 327 
However, programs for the treatment of syphilis with organic arsenic compounds 328 
could last for 18 months, had serious side-effects and often also required 329 
alternating with bismuth or mercury treatments. Silver arsphenamine and silver 330 
neoarsphenamine  and bismuth arsphenamine sulphonate also found therapeutic 331 
use (Gibaud and jaouen, 2010). Tryparsamide was the first arsenical that was 332 
clinically effective in treating African sleeping sickness (Trypanosomiasis), but 333 
resistance in Trypanosoma brucei was reported in the early 1930’s, a decade after 334 
introduction of the drug. The arsenical compounds melarsoprol (Arsobal
®
) and 335 
melarsonyl are still used to treat sleeping sickness, and have been used to treat 336 
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other diseases including amoebic dysentery, despite serious side effects including 337 
blindness (Joliffe 2003; Jones 2007, Gibaud and Jaouen 2010), while others such as 338 
arsenilic acid (Atoxyl, 4-Aminophenylarsonic Acid), have been largely discontinued 339 
as treatments due to their toxicity (Gibaud and Jaouen, 2010). Carbarsone was 340 
introduced as an antiprotozoal organoarsenical in the early 1930’s, followed by 341 
diphetarsone and arsthinol in the 1950’s. They were withdrawn from market in the 342 
1990’s  because of the association of arsenic exposure to a variety of abnormal 343 
growths/tumours (Gibaud and Jaouen 2010). 344 
In higher organisms arsenic is carcinogenic, with a range of potential mechanisms 345 
involved including genotoxicity, DNA methylation and cell proliferation alterations, 346 
oxidative stress, co-carcinogenesis and tumour promotion (Hughes, 2002). Despite 347 
the reduction in use of arsenic as an antimicrobial there has been renewed interest 348 
in arsenic as an anticancer drug. In the mid-1990s arsenic trioxide was investigated 349 
as a treatment for acute promyelocytic leukemia (APL) and received U.S. FDA 350 
approval in 2000 as a sterile injectable arsenic trioxide solution TRISENOX
 
351 
(Slejkovec et al 2011). 352 
 353 
Antimony 354 
Antimony may have been used as long as arsenic has been in medicine. In 355 
agriculture, tartar emetic (antimony potassium tartrate; C
4
H
4
KO
7
Sb·1/2 H
2
O), has 356 
been used in the treatment of leishmaniasis, schistomiasis, trypanomiasis, 357 
bilharziasis and ascariasis in domestic and farm animals in the 19th and early 20th 358 
centuries, and tartar emetic was also used as a pesticide spray on crops. 359 
Antimony was used as a cosmetic or in ointments in skin treatments in biblical 360 
times, and became popular in medicine during the 18th Century with uses of it 361 
including treatments for smallpox, syphilis, dropsy and agues (McCallum 1977). The 362 
toxic properties of antimony metal were clearly established in the 16th century and 363 
the powerful emetic effect of antimony was known in Roman times. This property of 364 
antimony was exploited in the 17th and 18th centuries to induce therapeutic 365 
vomiting, sweating and purging through ingestion of antimony either from drinking 366 
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wine which had stood for 17-24 hours in an antimony cup, or through swallowing a 367 
“perpetual pill” made from antimony, which soon reemerged from the patient. 368 
Tartar emetic was also used to induce vomiting in patients, and in tropical 369 
medicine, tartar emetic has been used as a treatment for schistomiasis. Other 370 
antimony compounds are still used as first-line treatment of visceral leishmanniasis 371 
and as treatments for schistomiasis in humans (Sadler and Guo 1999; Ashutosh et 372 
al., 2007; Ge and Sun 2007; Sundar and Chakravarty, 2010; Perry et al., 2011), 373 
though resistance to antimony drugs in Leishmania donovani, and Leishmania 374 
infantum in the Bihar region of the Indian subcontinent is now very high.  375 
Resistance in L. donovani to sodium stibogluconate (Pentostam) and meglumine 376 
antimonite (Glucantime) has been shown experimentally to be as a consequence of 377 
exposure of L. donovani  in a mouse model to levels of arsenic equivalent to those 378 
that humans are exposed to in arsenic contaminated drinking water from Bihar 379 
(Perry et al., 2013). 380 
 381 
Metal ion toxicity 382 
Despite the documented historical use of antimicrobial metals, understanding of the 383 
detailed toxic effects of different metal ions and metalloids on bacteria are arguably 384 
incomplete. However, it is clear that the chemistry of the metals drives the biology,  385 
in terms of metal bioavailability, the biological effects that a metal will have on 386 
cells, and the resistance mechanisms that bacteria can use to detoxify or remove 387 
the metals.  388 
Mechanisms of metal toxicity are generally agreed to be as a consequence of the 389 
metal ions’ affinity for cellular components and biomolecules, or the stability of 390 
metal-biomolecule complexes formed, although the consequences can be varied. 391 
Metals and metalloids can exert toxic effects in a number of different ways: by 392 
binding to or blocking functional groups in biological molecules, by displacing 393 
essential metals in enzymes, binding to the cellular thiol pool, or participating in 394 
chemical reactions in the cell that are harmful. Ultimately the deleterious effects 395 
reported include damage to proteins, DNA and biological membranes, interference 396 
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in enzyme function and cellular processes, and oxidative stress (Nies, 1999; 397 
Hobman et al., 2007). 398 
There have been different attempts to group metals based on their ligand affinity or 399 
toxicity, leading to rather vague classifications like “heavy metals” or “toxic metals” 400 
(Duffus 2002).  The two classifications that are the most widely accepted 401 
descriptors of the potential for interactions of metal ions with biological ligands are 402 
the Irving-Williams series of divalent metal ion ligand affinities, and the 403 
classification of metals into Lewis acids. The Irving-Williams series of ligand affinity 404 
for essential divalent metal ions clearly demonstrates the affinity of biological 405 
molecules for first row transition metals: Ca
2+
 <Mg
2+
 <Mn
2+
 < Fe
2+
 <Co
2+
 <Ni
2+
 406 
<Cu
2+
 > Zn
2+
 and shows that divalent copper has a strong affinity for biological 407 
molecules, suggesting that it can displace other metals from the first row of 408 
transition metals from them (Waldron and Robinson, 2009). Another way of 409 
measuring the toxicity of metal ions is to consider their strength as Lewis acids. 410 
Hard Lewis acids (small, non-polarizable electron sheath) prefer ionic coordination 411 
to oxygen containing ligands. Soft Lewis acids (with a large, polarisable electron 412 
sheath) prefer covalent coordination to soft Lewis bases; primarily S and N ligands: 413 
cysteine sulphydryls and nitrogen imidazoles. Intermediate Lewis acids will 414 
relatively stably coordinate to hard and soft donor ligands (Table 1). The metals 415 
and metalloids that are known to be toxic are largely but not exclusively soft Lewis 416 
acids which are likely to be able to displace intermediate and hard Lewis acids from 417 
cysteine sulphydryls because of their higher affinity for them.  418 
In addition to effects caused by the higher affinity of soft Lewis acids for ligands, 419 
oxidative stress is one other proposed mechanism of toxicity for some metals. 420 
Redox-active metals such as Cu, Cr, Fe and V, as well as redox-inactive metals and 421 
metalloids such as As, Cd, Hg, Ni, Pb and Sb can be involved in cellular oxidative 422 
stress damage. Although arsenate and mercuric ions can be reduced intracellularly 423 
they do not catalyse one electron transfer reactions and consequent free radical 424 
generation, such as copper, iron, chromate and vanadate do. For redox-active 425 
metals, generation of hydroxyl radicals via Fenton-like reactions is believed to be 426 
the probable mechanism by which oxidative stress occurs. For redox-inactive 427 
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metals and metalloids the potential mechanism of oxidative stress generation is 428 
that they bind to and inactivate cellular thiols, which normally quench reactive 429 
oxygen species that are generated during normal cellular metabolism, or can be 430 
redox metal catalysed, or metal-catalyzed oxidation of reduced glutathione can also 431 
generate hydrogen peroxide.  Recent evidence suggests that iron-sulphur clusters 432 
in enzymes are key targets for toxic metals (Hobman et al., 2007; Macomber and 433 
Imlay 2009; Xu and Imlay 2012) 434 
 435 
The broad mechanisms of toxicity for each of the commonly used antimicrobial 436 
metals are given below: 437 
 438 
 439 
Mercury  440 
Mercury is the most toxic metal to Escherichia coli (Nies 1999). Mercury toxicity has 441 
been attributed to the inactivation of enzymes and interference with other protein 442 
functions by the tight binding of mercuric ions to thiol and imino nitrogen groups in 443 
them, or displacement of other metal cofactors from enzymes. Mercuric ions also 444 
bind to nucleotides and lipids, interfering with DNA function and contributing to lipid 445 
peroxidation. Mercuric ions and organomercurials have the ability to rapidly pass 446 
through biological membranes, and organomercurials are highly lipid soluble 447 
(Clarkson and Magos, 2006). 448 
 449 
Copper  450 
Copper carries out an essential role as an electron donor/acceptor in many 451 
enzymes, but copper can also take part in Fenton-like reactions leading to the 452 
generation of hydroxyl radicals, hydrogen peroxide and superoxide, which can 453 
cause cellular damage (reviewed in Grass et al., 2011). This has been generally 454 
accepted as the major mechanism for Cu toxicity. However, recent experimental 455 
evidence from experiments in liquid culture has shown that copper mediated ROS 456 
generation occurred largely in the periplasm of E. coli, so the importance of ROS 457 
generation by copper as a cellular toxicity mechanism has been under debate 458 
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(Macomber et al., 2007). Gram-positve bacteria lack a periplasm, and although 459 
many are tolerant to hydrogen peroxide (Solioz et al., 2010), recent evidence from 460 
S. aureus shows oxidative stress resistance and protein misfolding repair 461 
transcriptional responses, and hydrogen peroxide scavenging defence (Baker et al., 462 
2010).  According to the Irving-Williams series copper has a higher affinity than 463 
other first row transition metals for ligands, and displacement of Fe from Fe-S 464 
clusters by copper in liquid culture experiments has been reported to be an 465 
important mechanism of copper toxicity (Macomber and Imlay 2009). There is also 466 
a role for copper and ROS in phagosome killing of bacteria (Reviewed in German et 467 
al. 2013) 468 
The rapid killing of bacteria on solid copper surfaces is thought to be due to cellular 469 
damage caused by very high local concentrations of copper dissolving from the 470 
surface, which causes membrane rupture, coupled with ROS generation causing 471 
further cellular destruction including degradation of plasmid and chromosomal DNA 472 
(Grass et al., 2011). 473 
 474 
Silver  475 
Silver (as well as gold) is the second most toxic metal to E. coli (Nies 1999). Silver  476 
ions cause the inhibition of respiration, membrane damage, and destruction of the 477 
proton motive force. The interaction of Ag
+
 with thiol groups in membrane 478 
proteins/enzymes is thought to be a major mechanism of toxicity, with data 479 
suggesting that the key toxicity event is interactions between Ag
+
 and respiratory 480 
chain enzymes (Holt and Bard 2005). Proteomic studies have shown that ionic and 481 
nanoparticle silver causes destabilization of the outer membrane, collapse of the 482 
cytoplasmic membrane potential and depletion of intracellular ATP levels in E. coli, 483 
consistent with interference with the respiratory chain (Lok et al. 2006; Du et al. 484 
2012).  Other evidence suggests that although still toxic to bacteria under 485 
anaerobic conditions, under aerobic conditions intracellular Ag
+
 ions also cause 486 
reactive oxygen species (ROS) generation and interference with DNA replication 487 
(Park et al., 2009), increased membrane permeability and increased sensitivity to 488 
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antibiotics (Morones-Ramirez et al., 2013).  There is some disagreement on which 489 
ROS are important in this mechanism of Ag
+
 mediated damage. Park and co-490 
workers suggest Ag
+
 ion mediated superoxide radical generation in E. coli and S. 491 
aureus  (Park et al., 2009), whilst in S. epidermidis Gordon and co-workers suggest 492 
generation of hydroxyl radical ions through release of iron from proteins by Ag
+
 493 
ions binding sulphydryl groups, leading indirectly to hydroxyl radical formation 494 
(Gordon et al., 2010).  Other work in Vibrio cholera showed that low levels of Ag
+
 495 
causes collapse of the proton motive force, proton leakage, and the cytoplasmic 496 
membrane is the major target for low levels of silver ions (Dibrov et al., 2002) and 497 
in Staphylococcus aureus silver cations also cause rapid and extensive loss of 498 
membrane integrity (Randall et al., 2012).   499 
 500 
Arsenic and antimony 501 
Arsenic toxicity depends on the nature of the arsenic compound. Inorganic arsenic 502 
toxicity is through allosteric inhibition of essential metabolic enzymes, with arsenite 503 
being more toxic than arsenate (Cooksey 2012). Arsenate is an analogue of 504 
phosphate and can enter cells via phosphate uptake systems and inhibits oxidative 505 
phosphorylation. Arsenite can enter cells via aquaglyceroporins, and binds to 506 
sulphydryl groups in proteins, and has been reported to bind to the vicinal thiols in 507 
pyruvate dehydrogenase and 2-oxo-glutarate dehydrogenase, affecting cellular 508 
respiration (Oreland and Stolz 2003). There is evidence that the presence of arsenic 509 
in cells leads to the generation of reactive oxygen and nitrogen species. One known 510 
mechanism for this is that Arsine (ASH
3
) and methylated derivatives can generate 511 
methylarsinyl peroxyl radicals, which damage DNA (Cooksey 2012), but  inorganic 512 
arsenic has also been implicated in reactive oxygen species generation, and 513 
disruption of signal transduction pathways (Kumagai and Sumi, 2007).  Arsenic and 514 
antimony share some chemical and toxicological properties, and therefore may 515 
share modes of toxicity. 516 
 517 
 518 
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Bacterial metal ion homeostasis and resistance to toxic metals 519 
The natural exposure of bacteria to bioavailable metals (both essential and toxic) 520 
has occurred over billions of years since the expansion of oxic environments that 521 
accompanied the great oxidation event (Barkay et al., 2010) and this exposure has 522 
likely been the driver for the evolution of the ability of microorganisms to control 523 
cellular levels of these bioavailable oxidised metal ions. Sometimes, these metals 524 
are found in high concentrations due to volcanic activity or other natural geological 525 
events. Bacteria have also been exposed to lethal concentrations of these metals 526 
through anthropogenic releases of toxic metals into the environment through 527 
mining, smelting, manufacture, fossil fuel burning and numerous other industrial 528 
applications, often at high localized concentrations; as well as the deliberate use of 529 
metals as antimicrobials and pesticides. Thus bacteria have evolved mechanisms to 530 
acquire essential metals, control the intracellular levels of these metals, and 531 
eliminate metals that in excess are deleterious. Similarly systems for removing 532 
from the cell, or modifying, purely toxic metals have also evolved and have been 533 
selected.  534 
Antimicrobial metals have multiple and different cellular targets, and there are 535 
limited options available for bacteria to mitigate or nullify the effects of metal 536 
toxicity.  Therefore, the potential resistance strategies that they can employ are 537 
limited to extracellular or intracellular sequestration of the metal, reduction in 538 
permeability, alteration of target sites, enzymatic detoxification, or efflux of the 539 
metal ions (Hobman and Brown 1997). These resistance mechanisms are 540 
conceptually similar to the possible mechanisms of antibiotic resistance (Courvalin 541 
2008).  Most of the mechanisms of resistance to metals that have been well 542 
characterized at the genetic level in bacteria are enzymatic detoxification, or efflux 543 
of the metals from the cell. This is because unlike organic antimicrobial compounds 544 
which can be broken down or inactivated by enzymatic cleavage, metals are 545 
immutable, and bacterial metal import systems or porins are not sufficiently 546 
discriminatory to allow in to the cell only metal ions that are required, and metal 547 
ion chaperones may also be subverted to bind to the “wrong” metal.  548 
 549 
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Mechanisms of antimicrobial metal resistance. 550 
Although mechanisms such as methylation or demethylation of metals, (which are 551 
often by-products of normal cellular metabolism) or generalized antimicrobial efflux 552 
through multidrug efflux systems, and stress response mechanisms, may contribute 553 
to fortuitous metal ion tolerance /resistance or damage repair, specific metal ion 554 
resistance mechanisms are usually characterized by a metal ion specific response 555 
regulator, which controls the expression of structural resistance genes. The 556 
products of these genes produce a metal ion specific efflux protein or protein 557 
complex, and/or enzyme(s) which alter the metal ion into a less toxic form to the 558 
bacterial cell. There may be other proteins encoded by the resistance mechanism, 559 
their functions ranging from metal ion chaperone to metal ion transporter or metal 560 
ion reductase. The simplest general mechanism of resistance is therefore a metal 561 
specific regulator, which controls expression of a metal ion efflux system.  562 
The specific resistance mechanisms for Hg, Cu, Ag, As/Sb will be discussed in detail 563 
below. 564 
 565 
Mercuric ion resistance. 566 
Resistance to mercuric ions is believed to be an ancient resistance mechanism, 567 
evolving after the biosphere became widely oxygenated,  and has been found 568 
widely in bacteria and Archaea (Barkay et al., 2010). The mechanism of mercuric 569 
ion resistance to inorganic mercuric ions (narrow-spectrum resistance) is unusual 570 
for a metal ion resistance mechanism and counter-intuitive (Figure 1). Rather than 571 
direct efflux of the metal, the simplest inorganic mercuric ion resistance operon in 572 
Gram-negative bacteria, from Tn501, encodes proteins that chaperone divalent 573 
mercuric ions (Hg
2+
) in the periplasm using MerP. Hg
2+
 ions are imported across the 574 
cytoplasmic membrane via MerT into the cytoplasm, where they are reduced to 575 
essentially non-toxic metallic mercury (Hg
0
) by mercuric reductase (MerA). Metallic 576 
mercury is volatile at room temperature and pressure and leaves the bacterial cell 577 
by passive diffusion. Mercuric ion resistance is a very good example of how a 578 
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resistance mechanism is determined by the chemistry of the metal, as MerA 579 
requires reducing equivalents to reduce Hg
2+
 to Hg
0
 and has to import Hg
2+
 to the 580 
cytoplasm in order to do this. MerP and MerT appear to prevent Hg
2+
 from 581 
damaging the cell during this process (Morby et al., 1995). In Gram-negative 582 
bacteria, regulation of the mer mercury resistance operon is through the activator 583 
MerR, with secondary regulation of the operon via MerD (reviewed in Brown et al., 584 
2003).  Resistance to organomercurials (or broad spectrum mercuric ion resistance) 585 
is conferred via organomercurial lyase (MerB).  MerB cleaves the C-Hg bond in 586 
organomercurial compounds, working with a narrow spectrum mer operon, and is 587 
regulated by an organomercurial responsive MerR. MerE is an additional inorganic 588 
and organic mercury importer (Kiyono et al., 2009). Other Gram-negative mercuric 589 
ion resistance operons encode additional mercuric ion import proteins (such as 590 
MerC in the Tn21 mer operon (Sahlman et al., 1997) and MerF in pMER327/419 591 
(Wilson et al., 2000; Hobman et al., 1994)). Most of the work on understanding 592 
mercury resistance has come from studies on the classic mercury resistances from 593 
Tn501 and Tn21 in Gram-negative bacteria.  594 
The mechanism of mercuric ion resistance in Gram-positive bacteria is broadly the 595 
same as that in Gram-negative bacteria, but details of the regulation and mercuric 596 
ion import systems differ slightly. The mer operons in Gram-positive bacteria have 597 
been best characterized in the plasmid pI258 mer from S. aureus and in different 598 
Bacillus strains. The S. aureus mer resistance contains merR, merA, merB and 599 
merT homologues, and some additional open reading frames, as do the Bacillus mer 600 
resistance operons, which confer broad spectrum mercury resistance (Chu et al., 601 
1992; Gupta et al., 1999).  There is now evidence that mercury resistance in some 602 
S. aureus strains is carried on the SCC
mercury 
element (Staphylococcus Cassette 603 
Chromosome reviewed in Malachowa and DeLeo, 2010). There are excellent and 604 
comprehensive reviews of mercuric ion resistance in bacteria (Summers et al., 605 
2003; Barkay and Wagner-Döbler, 2005). 606 
 607 
Copper homeostasis and resistance. 608 
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Copper homeostasis and copper resistance mechanisms have evolved because 609 
copper is an essential metal that can be toxic at higher intracellular concentrations, 610 
and copper is involved in host defence against pathogens.  611 
Bacterial cells have systems that control “normal” levels of copper and others that 612 
confer resistance to very high levels of copper. In E. coli, there are two 613 
chromosomally encoded copper homeostasis mechanisms, the cue and cus 614 
systems, both of which have components that modify the charge in ionic copper, 615 
and efflux it (the model for the mechanism is shown in Figure 2).  In the cue 616 
system, a MerR family copper responsive transcriptional activator, CueR, regulates 617 
expression of a copper efflux P1-type ATPase, CopA; and of CueO, a multicopper 618 
oxidase (Outten et al., 2000; Peterson and Moller, 2000; Stoyanov et al., 2001). In 619 
the cus system, a two component regulator CusRS activates expression of cusCFBA, 620 
CusCBA is a tripartite RND (resistance-nodulation-cell division) family silver/copper 621 
effluxer and CusF a periplasmic metallochaperone (Munson et al., 2000). Whilst the 622 
cue system is induced under very low external copper concentrations, the cus 623 
system has been reported to be induced under higher external levels of copper, and 624 
may be important under anaerobic conditions (Munson et al., 2000). The AcrD and 625 
MdtABC multidrug efflux pumps in Escherichia coli have also been reported to efflux 626 
Cu and other antimicrobials when NlpE, an outer membrane lipoprotein, which 627 
functions during envelope stress responses, is overexpressed (Nishino et al., 2010), 628 
and in Salmonella, enterobactin and TolC are involved in copper detoxification 629 
(Pontel et al., 2014).  630 
In addition to the cue and cus systems some E. coli strains isolated from pigs fed 631 
on copper supplemented feed carry a plasmid-borne copper resistance system, pco, 632 
which confers additional copper resistance (Tetaz and Luke, 1983; Brown et al., 633 
1995). The pco copper resistance from E. coli plasmid pRJ1004 contains seven open 634 
reading frames, designated pcoABCDRSE (Rouch and Brown 1997). The current 635 
model for the mechanism of resistance to copper salts conferred by pco is also 636 
shown in Figure 3. Gene expression from the pco operon is regulated by PcoRS, a 637 
two component regulator system homologous to the CopRS, CusRS and the SilRS 638 
regulators (from the pMG101 silver resistance plasmid) (Munson et al., 2000).  639 
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PcoR regulates expression of the pcoABCD genes from one promoter and pcoE from 640 
a separate promoter (Rouch and Brown 1997). PcoA, C and E are periplasmic 641 
proteins, PcoB an outer membrane protein and PcoD an inner membrane protein.  642 
PcoA is a multicopper oxidase, and may have a similar function to CueO, oxidizing 643 
Cu(I) to less toxic Cu(II). PcoC is a copper chaperone (Djoko et al., 2008) and PcoE 644 
may act as a periplasmic first line of defence copper ‘sponge’ protein, binding 645 
copper whilst the remainder of the Pco proteins are expressed (Zimmermann et al., 646 
2012). PcoB is a predicted outer membrane protein that may interact with PcoA, 647 
and which could either oxidize Cu(I) to the less toxic Cu(II), or act to sequestrate 648 
oxidized catechol siderophores, which themselves could reduce cupric ions to the 649 
more toxic cuprous ions. (CueO may also act to prevent this by directly oxidizing 650 
catechols (Grass et al., 2004).  PcoC and PcoD are required for full copper 651 
resistance (reviewed in Rensing and Grass 2003). Homologues of pco (albeit lacking 652 
some of the genes seen in the pRJ1004 pco resistance) and called cop have been 653 
identified in plant saprophytic and pathogenic bacteria from crops treated with 654 
copper fungicides (Bender and Cooksey, 1987; Cooksey et al., 1990).  655 
Gram positive bacteria have a different copper homeostasis mechanism, which is 656 
probably best understood in Enterococcus hirae- (reviewed in Solioz et al., 2010). 657 
This mechanism involves import of copper into the cytoplasm via (a different) 658 
CopA, an ATPase;  binding of excess cytoplasmic copper by a copper chaperone 659 
(CopZ), which donates it to either a copper export ATPase (CopB) or to CopY, which 660 
is a copper responsive repressor of gene expression for the E. hirae cop operon. 661 
The mechanism of copper homeostasis in Lactococcus lactis appears to be different 662 
as both CopA and  CopB act as efflux ATPases. Recently a plasmid encoded a 663 
copper efflux ATPase and a multicopper oxidase  have been found in Listeria 664 
monocytogenes (Kuenne et al., 2010).  A CPx-type ATPase copper resistance efflux 665 
pump encoded by the tcrB gene has also been found on a conjugative plasmid 666 
carried by Enterococcus faecium from pigs and is related to the copYZAB operon in 667 
E. hirae. This has also found in farmed chickens and calves and is linked to 668 
macrolide and glycopeptide resistance (Hasman and Aarestrup 2002). CsoR, a 669 
copper sensing repressor regulates expression of the copZA promoter in response 670 
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to intracellular copper in Bacillus subtilis and Staphylococcus (Baker et al., 2011; 671 
Liu et al., 2007; Smaldone and Helmann 2007). 672 
There are several excellent and comprehensive review articles on copper resistance, 673 
which describe the genetics and biochemistry of resistance and the role of copper 674 
resistance in pathogenicity,  in great detail (e.g. Chaturvedi and Henderson, 2014; 675 
Dupont et al., 2011; German et al., 2013; Osman & Cavet  2008; Rensing and 676 
Grass 2003; Solioz et al., 2010 ). 677 
 678 
Silver tolerance and resistance  679 
Although bacterial silver resistance has been reported sporadically since the 1960’s 680 
(for reviews see Clement and Jarrett, 1994; Silver et al., 2006; Chopra 2007, 681 
Mijnendonkx et al., 2013) the pMG101 sil system remains the only one 682 
characterized in any detail at the genetic level. The 182 kb transferrable IncHI-2 683 
group plasmid pMG101 from Salmonella enterica serovar Typhimurium was isolated 684 
in 1973 from fatal infections in a burns unit in Massachusetts General Hospital, 685 
Boston, USA. Plasmid pMG101 confers resistance to Cm, Ap, Tc, Sm, Su, Hg, Te 686 
and Ag (McHugh et al., 1975; Gupta et al., 1999). The proposed silver resistance 687 
mechanism has been predicted via DNA sequencing and comparison to the E. coli 688 
cop and cus copper resistances. Several small subclones of the sil operon confer 689 
partial silver resistance (Gupta et al., 1999). The cus system is known to confer 690 
resistance to low levels of silver (and was called agr by Franke et al., 2001; 2003, 691 
and cus by Munson et al., 2000)) and some of the sil genes from pMG101 are 692 
closely related to the cus genes.  There is 71% identity between SilC and CusC, 693 
67% identity between SilB and CusB and 87% identity between SilA and CusA, 694 
which form the efflux protein complexes SilCBA and CusCBA, respectively (Gupta et 695 
al., 1999). The proposed mechanism of silver resistance is shown in Figure 4, in 696 
which a two component silver responsive transcriptional regulation system SilRS 697 
(homologous to CusRS and PcoRS) controls expression of a silver efflux ATPase, 698 
SilP , the tripartite SilCBA silver effluxer and SilF, which is believed to be a 699 
periplasmic silver chaperone. Several other genes or open reading frames are 700 
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present in the sil system. SilE has a role in periplasmic silver binding (Silver, 701 
personal communication) and there is a small open reading frame between silA and 702 
silP named orf105 which could encode a hypothetical protein of 105 amino acids, 703 
but which is of unknown function. There is another silver resistance system in the 704 
environmental bacterium Cupriavidus metallidurans CH34, which is composed of 705 
silCBA and located on one of two large plasmids, pMOL28 (Mergeay et al., 2003, 706 
Monchy et al, 2008)  707 
Homologues of the sil system have been detected using sil specific primers in 708 
IncH1-2 group plasmids from Gram-negative bacteria (Gupta et al., 2001), in oral 709 
bacteria (Davis et al. 2005), in nosocomial isolates of Enterobacter cloacae (Kremer 710 
and Hoffmann, 2012), a silver resistant E. cloacae leg ulcer isolate (Sütterlin et al., 711 
2012), some Gram-negative bacteria isolated from wounds (Woods et al., 2009) 712 
and surprisingly in S. aureus (Loh et al., 2009). There are also some reports of 713 
silver resistant pathogens which carry the sil genes that were isolated from burns 714 
units and even from the silver containing burns creams (Pirnay et al., 2003). 715 
 716 
Arsenic and antimony resistance. 717 
Arsenic resistance is very widespread amongst both Gram-negative and Gram-718 
positive bacteria, probably reflecting the wide distribution of arsenic in the 719 
environment and its use as an antimicrobial (Silver and Phung 2005).  Arsenic 720 
resistance was first identified in Gram-positive bacteria by Novick and Roth (1968), 721 
and in Gram-negative bacteria shortly afterwards.  722 
Arsenic resistance operons in bacteria confer resistance to arsenite (AsIII), 723 
arsenate (AsV) and antimonite (SbIII). The minimum arsenic resistance operon 724 
consists of arsR, arsB and arsC, which encode respectively, an arsenite responsive 725 
trans-acting transcriptional repressor protein, an arsenite antiporter and an 726 
arsenate reductase. Some Gram-negative arsenic resistance operons (such as the 727 
E. coli plasmid-borne arsenic resistance carried on R773) also carry two additional 728 
genes: arsD and arsA. ArsA has an ATPase function, which binds as a dimer to ArsB 729 
forming an ATP energized effluxer, which is more efficient at arsenite efflux than 730 
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ArsB alone. ArsD has a minor role in transcription, but has recently been found to 731 
act as a metallochaperone for arsenite efflux via ArsAB (Lin et al., 2006). Previous 732 
work has shown that in the absence of ArsA, ArsB confers lower levels of arsenite 733 
resistance by translocating these ions into the periplasm using energy derived 734 
either from the proton pumping respiratory chain or from F
0
F
1
 ATPase (Dey and 735 
Rosen, 1995). The Gram positive arsenic resistance found on S. aureus plasmid 736 
pI258 is comprised of the simpler arsRBC system. The current model for arsenic 737 
and antimony resistance conferred by ars operons is shown in Figure 5.  738 
There is an additional chromosomal arsenic resistance mechanism that has recently 739 
been found in some bacteria (e.g. Alcaligenes faecalis, Thiomonas sp.). This 740 
mechanism involves the use of arsenate as a terminal electron acceptor in the 741 
absence of oxygen, with a respiratory arsenite oxidase from the periplasm and a 742 
respiratory arsenate reductase converting respectively, arsenite to the less toxic 743 
arsenate (as part of a chemolithoautotrophic lifestyle), and acting as a terminal 744 
electron acceptor during anaerobic heterotrophic growth. Some of these arsenate-745 
respiring bacteria also carry the classic arsenate resistance genes, and can tolerate 746 
very high levels of arsenate (Silver and Phung, 2005). 747 
 748 
Antibiotic and antimicrobial metal ion resistances are often carried 749 
on mobile genetic elements in bacteria from the ‘antibiotic era’. 750 
Bacterial resistance to antimicrobial metals in clinically important bacteria was first 751 
reported in the early 1960’s in S. aureus isolated from surgical wounds. This was 752 
attributed by Moore (1960) to the use of mercuric ions used to disinfect catgut used 753 
in sutures, and other workers to the use of mercury containing diuretics (Hall 1970) 754 
or disinfectants (Porter et al., 1982). Mercuric ion resistance (Hg
R
) was then found 755 
to be genetically linked to S. aureus penicillinase plasmids (Richmond and John, 756 
1964), and arsenic resistance was first identified in Gram-positive bacteria by 757 
Novick and Roth (1968) who found that S. aureus penicillinase plasmids carried 758 
resistance to arsenate, arsenite/antimony, lead, cadmium/zinc, mercury, and 759 
bismuth.  Meynell and Datta (1966) isolated  R (resistance) plasmids from clinical  760 
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Escherichia coli strains such as R46, which conferred tetracycline, ampicillin, 761 
streptomycin, sulphonamide and arsenic resistance, whilst Smith (1967) also found 762 
resistance to mercuric ions, nickel and cobalt in clinical isolates of Escherichia coli 763 
and Salmonella sp. These resistances were later found to be located on plasmids or 764 
mobile genetic elements such as transposons. Elek and Higney (1970) also 765 
identified arsenic, mercury and copper resistance in Escherichia coli causing urinary 766 
tract infections using resistogram typing.  One of these strains contained the classic 767 
R plasmid R773 which also conferred resistance to tetracycline and streptomycin. 768 
The Hammersmith Hospital Collection of resistance plasmids collected from the 769 
early 1960’s onwards- contained 25% Hg
R
 plasmids (Schottel et al., 1974 )- whilst 770 
other studies showed up to 60% of hospital isolate strains at that time were Hg
R
. 771 
Since then, metal ion resistance genes have been regularly detected in bacteria 772 
isolated from the clinic, environment, agricultural, domestic and wild animal, and 773 
human sources.  774 
The first descriptions of the mechanisms of antimicrobial metal resistance started in 775 
the late 1960’s and the detailed mechanisms of resistance and the genes encoding 776 
the resistance mechanisms have been studied since then.   777 
More recently clinical interest in antimicrobial metal ion resistances has decreased, 778 
but there is increasing evidence that antibiotic and metal ion resistances are linked, 779 
as they are carried on the same mobile genetic elements – such as transposons and 780 
plasmids (Frost et al., 2005; Baker-Austin et al., 2006;  Summers, 2006; Mindlin 781 
and Petrova, 2013).  782 
 783 
Antimicrobial metal ion resistances were carried on mobile genetic 784 
elements in bacteria from the ‘pre-antibiotic era’. 785 
Our first understanding of bacterial antimicrobial metal ion resistance came from 786 
clinical bacteria from the ‘antibiotic era’, which were originally isolated because they 787 
were resistant to antibiotics. However, subsequent investigations showed that as 788 
well as resistance to antimicrobial metals in contemporaneous strains of clinically 789 
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important bacteria, antimicrobial metal resistance was also present in ‘pre-antibiotic 790 
era’ clinical isolates stored by E.D.G. Murray in Hammersmith Hospital between 791 
1917-1954, (although very low numbers of these strains were antibiotic resistant).  792 
Within the collection there were significant numbers of strains carrying plasmid-793 
borne resistance to K
2
TeO
4 
(11/433), CuSO
4 
(68/433), NaAsO
2 
(61/433), but less to 794 
HgCl
2 
(3/433).  Resistance to silver was not tested (Hughes and Datta, 1983).  The 795 
incompatibility groups of these plasmids were the same as are found today (Datta 796 
and Hughes, 1983).  797 
 798 
Tn21 subgroup transposons- drug (resistance) mules 799 
One of the best known examples of how metal ion resistance and antibiotic 800 
resistance genes are genetically linked is the understanding that Tn21 family 801 
mercuric ion resistance transposons carry class 1 integrons. These integrons are 802 
not mobile themselves, but are responsible for the acquisition and expression of 803 
antibiotic resistance cassettes (Liebert et al., 1999).  804 
Sulphonamides were introduced into Japan during World War II, and streptomycin, 805 
chloramphenicol and tetracycline were introduced in 1950 to tackle serious 806 
Shigellosis problems. S. dysenteriae strains were isolated in 1952 that were 807 
resistant to sulphonamides, and isolation of strains resistant to sulphonamides, 808 
streptomycin, chloramphenicol and tetracycline first occurred in 1955 (reviewed in 809 
Watanabe 1963). Experimental findings that these antibiotic resistances could be 810 
transferred from Shigella sp. to Escherichia coli K-12 led to the realisation that 811 
these resistances were associated with “Resistance Transfer Factors” or plasmids.  812 
Plasmid R100 (also independently isolated as R222, or NR1) is a classic example of 813 
a multiresistance plasmid that was first isolated in Japan sometime during the early 814 
to mid-1950’s (Nakaya et al., 1960; Davies, 1995). R100 carries resistances to 815 
tetracycline, chloramphenicol, sulphonamides and aminoglycosides (Liebert et al., 816 
1999). The mercury resistance transposon Tn21 carried on R100 (NR1) can justly 817 
be regarded as the paradigm for a particular class of mercuric ion resistance found 818 
in Gram-negative bacteria, and for how a metal ion resistance transposable element 819 
  29 
performs another role, acting as a drug (resistance) mule carrying integron 820 
elements that acquire, reassort and express antimicrobial resistance genes. In the 821 
case of Tn21, In2, the integron carried by it contains the sulI, (sulfonamide 822 
resistance), qacE∆1, (partially deleted quaternary ammonium compound resistance) 823 
and aadA1 (aminoglycoside adenylyltransferase) resistance genes (Liebert et al., 824 
1999). So although Hg compounds are now rarely (if at all) used as antimicrobials 825 
in agriculture and medicine, class I integrons are being carried by mercuric ion 826 
resistance transposons in Gram-negative pathogens that are of current concern.  827 
Examination of the Hg
R
 plasmids from the Murray collection showed that the Hg
R
 828 
determinant carried on one of them was very similar to Tn21, (but was flanked at 829 
each end by copies of IS5075, lacked the integron, and had a small deletion at the 830 
site where In2 has inserted into the transposon) (Essa et al., 2003).  In a separate 831 
study a 10,000 year old Siberian permafrost bacterial isolate was found to contain a 832 
transposon that was virtually identical to Tn21, but lacked the integron (Kholodii et 833 
al., 2003). These preantibiotic era Tn21-like mercury resistances lacking In2 are 834 
consistent with a model for the stepwise evolution of Tn21 ancestor mercury 835 
resistance transposons into multiresistance transposons. 836 
Tn21 subgroup transposons conferring multiple antibiotic resistance and containing 837 
Class 1 integrons have subsequently been found widely in enterobacteria from 838 
commensal, clinical and environmental Gram negative bacteria (Zühlsdorf and 839 
Wiedemann 1992, Liebert et al., 1999, Wireman et al., 1997; Mazel et al., 2000, 840 
Levings et al., 2007; Partridge, 2011; and reviewed in Mindlin & Petrova 2013) 841 
(Table 2). Integron acquisition of antibiotic resistances including ESBLs (extended 842 
spectrum beta lactamases) (Novais et al., 2010) and A. Baumannii- abaR5 (Post et 843 
al., 2010, Post and Hall 2009) are of major concern, but perhaps of no surprise.  844 
Recently, evidence has emerged of highly efficient horizontal transfer of Tn21-845 
related transposable elements by natural transformation followed by chromosomal 846 
integration between unrelated bacterial species (Domingues et al., 2012). There are 847 
at least seven independent examples (including Tn21) of an integron insertion into 848 
a simple mercury resistance transposon into or close to res sites of the transposon 849 
Mindlin and Petrova, 2013). An important example of an evolutionarily distinct 850 
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multiresistance mer transposon is Tn1696 (Partridge et al., 2001) where In4 851 
inserted into a Tn5036-like transposon. Similar independent integron insertion 852 
events into mer transposons point to the major role of the mer transposon as the 853 
carrier of integron associated antibiotic resistances (a drug resistance “mule”) and 854 
may be one explanation for the frequency of mer transposon appearance in 855 
pathogens.  Correlation between high levels of antibiotic resistance and carriage of 856 
the merA gene has been noted in E. coli from human populations, with higher 857 
exposure of the human population to mercury correlating with higher levels of 858 
mercury and antibiotic resistance (Skurnik et al., 2010).   859 
Whole genome and whole plasmid sequencing of medically important bacteria is 860 
now showing the presence of Tn21-related multiresistance transposons in multiple 861 
strains- this will be discussed further later in this article (see Table 2).  862 
 863 
Microbial Genomes- snapshots of the evolution of pathogen 864 
resistance repertoires? 865 
The dramatic increase in the number of draft or complete microbial genome 866 
sequences being produced over the last ten years or so has provided us with 867 
information on the content of bacterial genomes and particularly with high 868 
throughput sequencing technologies, on the evolution of bacterial pathogens.  869 
These genome sequences also allow us to examine the prevalence of antimicrobial 870 
metal resistance in recent isolates of medically or agriculturally important bacteria, 871 
including the genomes of existing, “new”, emerging, and re-emerging pathogens, 872 
opportunistic pathogens and “Pathogenic commensals” (Alekshun and Levy, 2006). 873 
Many of these pathogens are niche pathogens, or opportunistic healthcare-874 
associated infections in critically ill or immune compromised patients. They also 875 
represent acute clinical problems because they are Multiply Drug Resistant (MDR) 876 
presenting challenges to treatment.  877 
What is the evidence from these genome sequences that antimicrobial metal 878 
resistances are contributing to the broader MDR problem? We have examined 879 
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evidence for carriage of mercury, copper/silver and arsenic/antimony resistance in 880 
microbial genome sequences, and will discuss them next. 881 
 882 
Mercury Resistance:  still here, but why? 883 
Mercury resistance transposons related to Tn21 and the similar Tn1696 can be 884 
found on pathogen plasmids or chromosomes, associated with antibiotic resistance 885 
cassettes carried on integrons. Table 2 shows examples of these resistances from 886 
recently sequenced pathogens, some of which were originally isolated when 887 
mercury was still used as an antimicrobial, others which were isolated more 888 
recently. Examples of more recently isolated mer transposons include those 889 
carrying the TEM-24 ESBL resistance in the integron (Novais et al., 2010), 890 
examples of multidrug resistance Acinetobacter baumanii, Yersinia pestis, 891 
Salmonella Typhimurium, and the recent  E. coli O104:H4 mass food-poisoning 892 
outbreak isolate from 2010 (see Figure 6). The widespread persistence of mercury 893 
resistance transposons in pathogens is at first sight surprising given that mercury 894 
compounds are apparently rarely used as antimicrobials. 895 
 896 
Copper and silver resistance: a previously under-remarked genetic 897 
linkage? 898 
The pMG101 plasmid-borne silver resistance (Gupta et al., 1999) and the 899 
independently isolated pco plasmid copper resistance (Tetaz and Luke 1984) are 900 
the most well characterized silver and copper resistances.  During the annotation of 901 
the genome sequence of the enterohaemmorhagic E. coli (EHEC) H10407 902 
(Crossman et al., 2010) we noted a chromosomal genetic arrangement where the 903 
pco and sil operons were adjacent to each other. Subsequent searches of other 904 
plasmid and genome sequences (see Table 3) have identified this arrangement (or 905 
similar) in a range of different Gram-negative bacteria, both on plasmids and on 906 
chromosomes (see Figure 6), including in the German E. coli O104:H4 isolate from 907 
the 2010 mass outbreak, avian pathogenic E. coli (Johnson et al., 2006), and 908 
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livestock isolates (our work, unpublished). This raises a number of unresolved 909 
questions regarding the contribution of sil and pco to silver and copper resistance, 910 
whether these contribute to in vivo survival of pathogens in macrophages, cross 911 
regulation and co-selection of these genes, as well as their mobility, and the 912 
consequences of this on MDR resistance- particularly in agricultural environments 913 
where high levels of copper are used in feed and as antimicrobials, but also in 914 
environments where silver is being used as an antimicrobial.  915 
 916 
Arsenic/antimony resistance:  not gone away, nor likely to? 917 
Bacterial arsenic and antimony resistance is at present of marginal interest to 918 
human medicine, but resistance is still found widely in bacteria of medical 919 
importance (Table 4). Environmental exposure to arsenic or antimony, the 920 
continued use of antimonite in treating Leishmaniasis, exposure of human 921 
populations to arsenic contaminated drinking water, (Perry et al., 2011, 2013), the 922 
use of arsenic compounds as rodenticides and the current and historic use of 923 
arsenic compounds in animal husbandry could all have provided direct selection for 924 
carriage of As/Sb resistance in the commensal and pathogenic microbial flora, and 925 
may still be doing so (Eppinger et al., 2012). Co-selection of arsenic resistance 926 
alongside other antimicrobial resistances in IncH1-2 plasmids has also been 927 
proposed as an explanation for the continued retention of arsenic resistance (Ryan 928 
and Colleran 2002), but equally environmental arsenical selection may be 929 
contributing to MDR selection. 930 
 931 
The state we are in and how we got here. 932 
Amidst the current worldwide concerns about antibiotic resistance, it could be 933 
argued that antimicrobial metal ion resistance is of marginal importance to medical 934 
microbiology, because antimicrobial metals are currently of limited clinical 935 
significance, though their use is growing again. Despite limited or discontinued use 936 
of these metals, mercury, copper, silver, arsenic and antimony resistances are still 937 
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here. These resistance genes are often found associated with antibiotic resistance 938 
gene cassettes on the same mobile genetic elements, or these antimicrobial metal 939 
resistances are carried on MDR elements, where presumably the fitness loss of 940 
carrying them is either unimportant, or outweighed by the advantages there are to 941 
carrying them, because resistance is still needed.  It is interesting that the 942 
transposons carrying mercury resistance genes found in clinically important 943 
pathogens are often carrying a far heavier “payload” of antibiotic resistance genes. 944 
The original “R” (Resistance) plasmids isolated in the 1960s and 1970s conferred 945 
multiple antibiotic and metal ion resistances on their hosts, and high levels of Hg
R
 946 
and As
R
 bacteria were found in healthcare environments.  It was reasonably 947 
assumed that this was at least in part due to mercury (Porter et al., 1982) and 948 
arsenic compounds being widely used in medicine.  There is current, and clear 949 
evidence, of the linkage of metal-ion and antibiotic resistance gene carriage in 950 
bacteria in sewage treatment plants (see Davies and Davies 2010 and references 951 
therein), as well as in terrestrial and aquatic environments (Berg et al., 2005; 952 
Stepanaskas et al., 2006; Wright et al., 2006; Wright et al., 2008; Skurnik et al., 953 
2010). Moreover, there is a considerable literature on the problem of antibiotic 954 
resistance/metal resistance co-selection (Stepanauskas et al., 2006 ; Baker-Austin 955 
et al., 2006 ; Singer et al., 2006 ; Aminov and Mackie 2007, Allen et al., 2010). So 956 
whilst the use of mercury and arsenic in medicine has declined, and copper and 957 
silver have limited uses, antimicrobial metal resistance genes to these (and other) 958 
metals are persisting, and are co-selected with other antimicrobial resistance 959 
genes.  960 
And herein lies the problem. Summers (2004, 2006) has already elegantly argued 961 
that although antimicrobial resistance has traditionally been viewed as a treatment 962 
(failure) problem, the propagation of resistance to antimicrobials is actually an 963 
ecological problem, and that both human and agricultural uses of antimicrobials 964 
have contributed to this situation. Summers (2006) has also argued that 965 
understanding the role of the agricultural and commensal microbiota and the 966 
mobile genetic elements  involved in resistance gene movement is also very 967 
important in understanding these multidrug resistance and transmission 968 
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phenomena. We can find nothing to disagree with there:  the role of commensal 969 
bacteria as a reservoir for antimicrobial resistance genes is now gaining more 970 
recognition (for example Fricke et al., 2008; Marshall et al., 2009) and it has been 971 
long recognized that antibiotic resistance in agricultural bacteria is a significant 972 
problem (reviewed in: Khatchatourians 1998, Wise et al., 1998; Levy and Marshall, 973 
2004; Silbergeld et al., 2008). The phenomenon of antimicrobial metal resistance 974 
gene emergence and spread is in our opinion conceptually identical to the problem 975 
of the evolution and dissemination of antibiotic resistance which was outlined by 976 
Courvalin (Courvalin, 2005, 2006). One strategy proposed to reduce antibiotic 977 
resistance is to attempt to delay the emergence and dissemination of resistance to 978 
new antibiotics (Courvalin 2006). Unfortunately we cannot delay the emergence of 979 
antimicrobial metal resistance. It has already happened, and those resistances are 980 
still apparently highly successful, widespread and mobile in Gram-negative bacteria, 981 
and may also be important in Gram positive bacteria such as S. aureus.  Is it now 982 
time to have a serious debate about the non-medical uses of antimicrobial metals in 983 
relation to the dissemination of MDR? Or are we too late? Will new formulations and 984 
uses of antimicrobial metals overcome existing resistance mechanisms? Or will 985 
lethal selection drive evolution of resistance?  986 
 987 
Conclusions 988 
Bacterial antimicrobial metal ion resistances, which have been found in pathogens 989 
and non-pathogens, were present long before microbiologists realized that these 990 
resistances existed.  Even now, the genetic elements encoding metal ion resistance 991 
appear to be playing a powerful role in facilitating MDR resistance and horizontal 992 
gene transfer, through co-carriage and/or co-selection of antibiotic resistance with 993 
the metal resistances. The presence of antimicrobial metal resistance genes in 994 
bacteria not only reflects the anthropocentric view of microbiology (Aziz, 2009), 995 
which is the history of human antimicrobial use in infectious disease (Toleman and 996 
Walsh 2011) but also microbial exposure to these metals from industry and 997 
agriculture; and predating all human uses: the exposure of microorganisms over 998 
millennia to localized high levels of bioavailable toxic metals from natural 999 
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environmental releases, and interactions with organisms that predate humans. The 1000 
continuing widespread presence of antimicrobial metal resistance genes often 1001 
intimately associated with other antimicrobial resistance genes suggests that it is 1002 
unlikely that they are going to go away soon, and we must take resistance gene co-1003 
carriage and co-selection into account when we think about strategies to combat 1004 
antimicrobial and antibiotic resistance. Persistence of these metal resistance genes 1005 
points to what the future for antibiotic resistance gene persistence could be. 1006 
 1007 
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Figure Legends 1740 
 1741 
Figure 1: Model of the Gram negative bacterial mercuric ion resistance 1742 
mechanism from Tn21. Modified from Hobman and Brown 1997; Barkay et al., 1743 
  63 
2003. Divalent mercuric ions (Hg
2+
) enter the periplasm via porins in the outer 1744 
membrane, where they bind to cysteine residues in MerP. They are then passed on 1745 
to the inner membrane located MerT and/or alternate importers MerC or MerF. 1746 
Mercuric ions are transferred via cysteine pairs in MerT and emerge in the 1747 
cytoplasm, where they are reduced by mercuric reductase (MerA) to Hg
0
. This is 1748 
volatile at room temperature and pressure, and leaves the cell as mercury vapour. 1749 
Expression of the mercury resistance structural genes are regulated by MerR. MerD 1750 
acts as a co-regulator of expression. In “broad spectrum” mercury resistances, 1751 
which confer resistance to inorganic and organic mercury compounds, “broad 1752 
spectrum” carry an organomercurial responsive MerR and encode an enzyme, 1753 
organomercurial lyase (MerB), which cleaves the organic moiety from mercury. 1754 
MerB is often found located between merA and merD. An additional importer MerE 1755 
is reported to import organomercurial ions (Sone et al., 2013) 1756 
 1757 
Figure 2: Model of the Escherichia coli chromosomal cue and cus copper 1758 
homeostasis/efflux mechanisms.  Modified from Stoyanov et al.,2001;  Outten 1759 
et al., 2000;  Munson et al., 2000; Rensing and Grass 2003).  Copper enters the 1760 
cytoplasm and induces expression of copA which encodes a copper efflux P1-type 1761 
ATPase and of CueO, a multicopper oxidase. Both genes are regulated by CueR, a 1762 
copper responsive MerR family regulator.  In the cus system, a two component 1763 
regulator CusRS activates expression of cusCFBA via phosphorylated CusR.  CusCBA 1764 
is a tripartite RND (resistance-nodulation-cell division) family silver/copper effluxer 1765 
and CusF a periplasmic metallochaperone. CusCBA effluxes Cu
+
 directly to the 1766 
outside the cell, and copper can directly enter the CusCBA complex from the 1767 
cytoplasm, the periplasm or from CusF.  1768 
 1769 
Figure 3: Model for plasmid-borne (pco) copper resistance from E. coli 1770 
plasmid pRJ1004.  Modified from Rensing and Grass 2003; Djoko et al., 2008; 1771 
Zimmermann et al., 2012. The pco system operates in addition to the chromosomal 1772 
cue and cus systems. The pco copper resistance from E. coli plasmid pRJ1004 1773 
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contains seven open reading frames: pcoABCDRSE (Rouch and Brown 1997). 1774 
Copper enters the periplasm, possibly through porins, and gene expression from 1775 
the pco operon is regulated by the two component sensor-kinase regulator system 1776 
PcoRS which responds to the presence of copper. Phosphorylated PcoR regulates 1777 
expression of the pcoABCDRS genes from one promoter and pcoE from a separate 1778 
promoter (Rouch and Brown 1997).  There is a likely role for pigments / catechol 1779 
siderophores in pco copper resistance, though this is not well understood.  PcoE 1780 
acts as a first line of defence, copper ‘sponge’ protein, binding copper in the 1781 
periplasm, whilst the other Pco proteins are expressed.  PcoA is a multicopper 1782 
oxidase, which oxidizes Cu(I) to less toxic Cu(II) bound to PcoC in the periplasm 1783 
(Djoko et al., 2008).  PcoB is a predicted outer membrane protein that may interact 1784 
with PcoA/C to export copper (Djoko ey al., 2008), or may act to sequestrate 1785 
oxidized catechol siderophores (Rensing and Grass 2003).  PcoD is an inner 1786 
membrane spanning protein which may import copper into the cytoplasm or PcoC 1787 
may provide copper to PcoD, for loading on to PcoA, which is exported to the 1788 
periplasm via the TAT pathway (Rensing and Grass 2003; Djoko et al., 2008).  1789 
 1790 
Figure 4: Hypothetical model for silver resistance encoded on Salmonella 1791 
Typhimurium plasmid pMG101. (Modified from Silver, 2006).  Silver ions (Ag
+
) 1792 
enter the cell, and are detected in the periplasm by SilS, the sensor component of a 1793 
two component silver responsive transcriptional regulation system SilRS. The SilRS 1794 
sensor/regulator regulates its own expression via phosphorylated SilR, and that of 1795 
silE, which is believed to have a role in periplasmic silver binding. SilRS also 1796 
regulates the expression of silCBA , silF, silP and a small open reading frame orf105 1797 
the product of which  is of unknown function.  SilCBA is a tripartite RND 1798 
(resistance-nodulation-cell division) family silver effluxer, SilF is believed to encode 1799 
a small periplasmic silver chaperone, and SilP is an efflux ATPase. The model 1800 
predicts SilCBA effluxes Ag
+
 directly to the outside the cell, and Ag
+
 (by homology 1801 
to the cus system) can directly enter the SilCBA complex from the cytoplasm, the 1802 
periplasm or from SilF. SilE may work like its homologue PcoE, as a periplasmic 1803 
metal binding “sponge” giving initial protection against Ag
+
 damage. 1804 
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 1805 
Figure 5: Arsenic and antimony resistance operon from E. coli plasmid 1806 
R773. (Modified from Silver 1998, Nies 1999, Kruger et al., 2013).  Arsenate 1807 
(ASO
4
3-
) As
5+
 and arsenite (AsO
2
-
) As
3+
 or antimonite (SbO
2
-
) can enter the E. coli 1808 
cell via specific or non-specific transport systems (arsenate can enter cells via the 1809 
phosphate import system). ArsR is an arsenite responsive trans-acting 1810 
transcriptional repressor protein which senses As
3+
 in the cytoplasm and regulates 1811 
expression of the structural arsenic resistance genes.  ArsC, is an arsenate 1812 
reductase, which is required to reduce arsenate to arsenite so that it can be 1813 
effluxed by ArsB, an arsenite antiporter. ArsA has an ATPase function, and binds as 1814 
a dimer to ArsB, forming an ATP energized effluxer, which is more efficient at 1815 
arsenite efflux than ArsB alone. ArsD has a minor role in transcription, but has 1816 
recently been found to act as a metallochaperone for arsenite efflux via ArsAB (Lin 1817 
et al., 2006).  1818 
 1819 
Figure 6: Tn21 family mercury resistance transposon from E. coli O104:H4 1820 
Tn21 family transposon from the sequenced enteroaggregative, 1821 
enterohaemorrhagic  E. coli German outbreak strain. The integron contains: 1822 
trimethoprim, sulphonamide (sulI and sulII), and aminoglycoside (aminoglycoside 1823 
phosphotransferase and aminoglycoside kinase) antibiotic resistance genes and 1824 
encodes a multidrug effluxer protein related to QacE and EmrE. Upstream of the 1825 
mercury resistance transposon is a tetracycline resistance gene cluster. 1826 
 1827 
Figure 7: pco/sil resistance gene clusters found in different bacteria. 1828 
H10407- Enterotoxigenic E. coli strain H10407; pLVPK- K. pneumoniae CG43 pLVPK 1829 
plasmid; Ent- Enterobacter sp. AgI isolated from the gut of Anopheles gambiae 1830 
mosquito; O104:H4- E. coli O104:H4 enteroaggregative/enterohaemmorhagic  1831 
strain from the 2011 German foodborne outbreak., Cit’ - Citrobacter sp.30_2 from 1832 
the human microbiome project-a human intestinal biopsy specimen. 1833 
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 Class A and Class B metal ions 
 
Class A (hard) metals 
Lewis acids (electron acceptors) of small size and low polarizability 
(deformability of the electron sheath or hardness) 
Li, Be, Na, Mg, Al, K, Ca, Sc, Ti, Fe(III), Rb, Sr ,Y, Zr, Cs, Ba, La, Hf, Fr, Ra, Ac, 
Th. 
 
Borderline (intermediate) metals 
V, Cr, Mn, Fe(II), Co, Ni, Cu(II), Zn, Ga, As, Rh, Pb(IV), Sn, Sb 
Class B (soft) metals 
Lewis acids (electron acceptors) of large size and high polarizability (softness) 
Cu(I), Pd, Ag, Cd, Ir, Pt, Au, Hg, Ti, Pb(II). 
 
 
Table 1:  Classification of metals in terms of polarizability (Modified from Niebor 
and Richardson 1980, Duffus et al., 2002). Class A metal ions form ionic bonds 
with oxygen containing ligands that are mobile and easily displaced, Class B 
metals form covalent bonds and prefer coordination to nitrogen and sulphur 
centres in biological molecules. 
 
Table 2 
 
Tn21 related mercury 
resistances 
Strain Genetic element Additional information Reference 
Aeromonas salmonicida 
subsp. salmonicida A449 
Tn21 subfamily composite 
transposon containing an In2 
integron encoding resistance 
to streptomycin/ 
spectinomycin, quaternary 
ammonia compounds, 
sulphonamides and 
chloramphenicol. 
Causative agent of 
furuniculosis in fish 
Reith et al., 2008 
Acinetobacter Baumannii 
AYE 
Tn21-like element contained 
within an 86 kb chromosomal 
“resistance island” (AbaR1) 
containing 45 antimicrobial 
resistance genes. 
Epidemic strain in French 
hospitals. Multiply antibiotic 
resistant. 
Fournier et al., 2006 
Acinetobacter Baumannii 
3208 
 
Chromosomal  resistance 
island AbaR5, carrying 
residual sequences of Tn1696 
Australia 1997 blood infection 
isolate  
Post and Hall 2009 
(Tn21-related transposable 
element carrying In4) 
Acinetobacter baumannii 
AB0057 
Tn21-like element contained  
within an 86 kb chromosomal 
“resistance island”  AbaR3  
USA 2005 MDR bloodstream 
isolate 
Adams et al., 2008 
Escherichia coli O42 Chromosomal Tn21- 
subfamily related Tn2411 
carrying mercuric chloride 
resistance and resistances to 
sulphonamide, streptomycin 
and ethidium bromide on an 
In2-like integron. Tn2411 is 
flanked by tetracycline and 
chloramphenicol resistances. 
Enteroaggregative E. coli 
type strain isolated in 
Bangladesh in 1970 
Chaudhuri et al., 2010 
Escherichia coli EHEC O26:H
−
 
strain O6877 
Plasmid pO26-CRL contains a 
Tn21 subfamily composite 
transposon containing an In2 
integron encoding resistance 
to mercuric chloride, 
trimethoprim, β-lactams, 
sulfathiozole, streptomycin, 
and kanamycin.   
Australian isolate of 
Enterohaemmorhagic E. coli 
isolated in 1990s  
Venturini et al., 2009 
Escherichia coli EAHEC 
O104:H4 TY2482 
Genomic island 3 (GI-3) German epidemic 
enteroaggregative 
haemorrhagic  E. coli 
outbreak 201. Multidrug 
resistant. Related to E. coli 
55989   
Grad et al., 2013 
Klebsiella pneumoniae Plasmid pFOX-7a  carrying a 
Tn1696 derivative Tn6234 
Outbreak in a neonatal 
intensive care unit. IncL/M 
plasmid carrying a Tn3-like 
transposon carrying  bla
TEM-1a
 
and Tn6234 carrying bla
FOX-7
 
(an AmpC-type ESBL beta 
lactamase) and other 
resistance determinants. 
Di Pilato et al., 2014 
Pseudomonas aeruginosa PA7 Tn21- like element  contained 
within a chromosomal 
“transposon dump” 
A non-respiratory clinical 
isolate from Argentina. 
Unusually antibiotic resistant 
and contains Tn21, Tn1721 
and Tn5393 
Roy et al., 2010 
Pseudomonas aeruginosa Plasmid R10003 Tn1696 carrying In4 
Originally isolated in 1970’s.  
Resistance to gentamicin, 
Partridge et al., 2001 
 
streptomycin, spectinomycin 
and chloramphenicol. 
Independent evolution by 
insertion of In4 into a 
Tn5036-like transposon 
Salmonella enterica serovar 
Typhi CT18 
Plasmid pHCM1 Is5075 flanked mer 
resistance related to Tn21 
Parkhill et al., 2001 
Salmonella enterica serovar 
Paratyphi A 
plasmid pAKU_1 incHI1 
group, similar backbone to 
pHCM1 and pRK27 
24kb composite multidrug 
resistant transposon 
Isolated in 2002 in Karachi, 
Pakistan. 
Holt et al., 2007 
Salmonella enterica serovar 
Typhimurium T000240 strain 
(DT12) 
This strain contains a unique 
82-kb genomic island, 
designated as GI-DT12, which 
contains a Tn2670-like 
composite transposon 
containing an integron, 
multiple antibiotic resistance 
genes and a Tn21-like 
mercury resistance. 
Isolated from a human 
gastroenteritis sufferer in 
2000. Fluoroquinolone 
resistant 
Izumiya et al., 2010 
Shigella  flexneri Plasmid R100 containing The index isolate of Tn21. Reviewed in Liebert et al., 
Tn21, Tn10 (Tetracycline) 
and a Tn9 homolog 
(Chloramphenicol) 
Isolated in Japan n the mid 
1950’s. Tn21 contains In2 
1999 
Other mercury resistances    
Staphylococcus aureus 
sequence type 239 (TW) 
Plasmid-pTW20_1 borne 
SCCmec (beta-lactamase) 
with SCCmercury and cadA 
ATPase in a region flanked by 
IS431. 
The chromosomal 
SCCmercury region contains 
streptomycin and 
erythromycin resistance. 
SCCmec carries ψTn554 
carrying cadmium resistance. 
Holden et al., 2010 
Staphylococcus aureus Tn6009- a combination of 
Tn916 and a mer operon 
Found in both Gram-positive 
and Gram-negative bacteria 
from oral and urine samples 
Soge et al., 2008 
Mycobacterium abscessus CIP 
104536T (ATCC 19977) 
Hg
R
 carried on a 23Kb 
plasmid similar to pMM23 
from M. Marinum 
Strain originally described in 
1953 from a human knee 
infection, but  M. abscessus 
strains recognized to cause 
pseudotuberculous lung 
disease, particularly in cystic 
fibrosis patients 
Ripoll et al 2009 
 
 
Table 2: Tn21-like mercury resistance transposons and associated integrons, and other mercury resistances,  in 
sequenced plasmids or bacterial chromosomes from pathogens. 
 
 
Strain Genetic element Additional information Reference 
Citrobacter sp. 30_2 pco/sil Reference genome for the 
human Microbiome project 
sequenced by the Broad 
Institute 
GenBank assembly 
GCF_00158355.2 
Cronobacter sakazakii  
BAA-894 
Chromosomal  location of 
pco/sil 
Type strain for bacterial 
meningitis associated with 
infant formula milk 
Kucerova et al., 2010 
Enterobacter cloacae subsp. 
cloacae  
ATCC 13047 
The strain is reported to 
encode 37 multidrug efflux 
proteins, 7 antimicrobial 
peptide resistance proteins, 
11 β-lactamases. Multiple 
metal ion resistances: 
chromosome: 2 x sil, 3 x ars, 
1 x mer and 1 x cop operon. 
Plasmid pECL_A: 1 x sil, 1 x 
ars, 2 x mer, 1 x cop  and 1 x 
ter 
Type strain Isolated in 1890 
from human cerebrospinal 
fluid by Edwin Oakes Jordan 
Ren et al., 2010 
Enterobacter hormaechei Plasmid pQC carried in E. 
hormaechi hospital outbreak 
strain.  
Resistance to 
aminoglycosides and third 
generation cephalosporins. 
Reduced sensitivity to 
fluoroquinolones 
Nationwide nosocomial 
outbreak in the Netherlands. 
Plasmid related to R478.  
Paauw et al., 2009 
Enterobacter sp. Ag1 pco/sil detected in the draft 
genome sequence of this 
strain 
Isolated from the gut of 
Anopheles gambiae mosquito 
Jiang et al., 2012 
Escherichia coli C   
ATCC 8739 
Chromosomal  location of 
pco/sil 
Test strain for testing 
antimicrobial handwashes 
and assaying antimicrobial 
GenBank accession number 
CP000946 
preservatives 
Escherichia coli  
H10407 
Chromosomal  location of 
pco/sil  
 
Enterotoxigenic E. coli (ETEC)  
type strain Bangladesh  
Crossman et al., 2010 
Escherichia coli APEC O1 Inc HI2 plasmid pAPEC-O1-R 
carrying pco/sil and 
resistance to tellurite, 
streptomycin, gentamycin, 
tetracycline, quaternary 
ammonium compounds and 
sulphonamides 
Plasmid found in Avian 
Pathogenic Escherichia coli 
isolates in USA. 
Johnson et al., 2006 
Escherichia coli EAHEC 
O104:H4 TY2482 
Pco/Sil carried on 
chromosome 
German epidemic 
enteroaggregative 
haemorrhagic E. coli outbreak 
2011 
Ren et al., 2013  and 
This article 
Klebsiella pneumoniae CG43 Plasmid pLVPK carrying sil, 
pco and Pb resistance 
IncHI-2 plasmid Taiwan, 
hospital isolate 
Chen et al., 2004 
Klebsiella pneumoniae Multiresistance plasmid 
pUUH239.2  carrying sil, pco 
and ars resistance with 
multiple antibiotic 
resistances. Resembles E. coli 
ST131 plasmids 
2005 nosocomial outbreak 
isolate from Sweden. CTX-M-
15 Extended spectrum beta-
lactamase 
Sandegren et al., 2012 
Serratia marcescens Plasmid R478 pco/sil. Also 
confers resistance to 
tetracycline, chloramphenicol, 
kanamycin, mercury, arsenic, 
and tellurite. 
IncHI-2 group plasmid 
isolated in USA in 1969.  
Gilmour et al., 2004 
Salmonella Typhimurium Plasmid pMG101contains sil. 
Also confers resistance to 
tetracycline, chloramphenicol, 
kanamycin, ampicillin, 
streptomycin, sulphonamide, 
Isolated from a Burns unit at 
Boston General Hospital, 
Boston, USA 1973. IncHI-2 
group plasmid containing 
prototypical sil operon.  
McHugh et al., 1975 
 
mercury, arsenic, and 
tellurite. 
 
Plasmid is partially 
sequenced. 
Sil only    
APEC Escherichia coli pAPEC-O2-R IncF plasmid, an 
avian pathogenic Escherichia 
coli transmissible R plasmid 
carrying sil and resistances to 
quaternary ammonium 
compounds, tetracycline, 
sulphonamides, 
aminoglycosides, 
trimethoprim and beta-
lactams 
An avian pathogenic 
Escherichia coli isolated from 
a chicken with colibacillosis. 
Johnson T.J., et al (2005) 
 
TABLE 3. Examples of pco/sil gene clusters in sequenced bacterial type strains and pathogens. 
 
 
Strain Genetic element Additional information Reference 
Acinetobacter Baumannii 
AYE 
Arsenic resistance contained 
within an 86 kb chromosomal 
resistance island (AbaR1) 
which is a composite 
transposon containing 45 
antimicrobial resistance 
genes. 
Epidemic strain in French 
hospitals. Multiply antibiotic 
and antimicrobial resistant. 
Fournier et al., 2006 
Acinetobacter baumannii 
AB0057 and related strains  
 
Multiple antimicrobial 
resistance: arsenate, 
mercury and multiple 
antibiotic resistance carried 
on AbaR3, which shares 
resistance island homology 
with AYE strain. 
Isolated in 2004 from a 
patient at Walter Reed Army 
Medical Center, USA.  
Adams et al 2008 
Acinetobacter baumannii 
3208  
Arsenic and multiple 
antimicrobial resistance 
carried on the AbaR5, similar 
to AbaR3. 
Isolated in 1997 in a hospital 
in Sydney, Australia, from a 
blood sample. 
Post and Hall 2009 
Burkholderia cenocepacia 
J2315 
Resistant to aminoglycosides, 
macrolides, β-lactams 
imipenem and piperacillin, 
Epidemic pathogen of cystic 
fibrosis patients. Isolated 
from the sputum of a CF 
Holden et al 2009 
cotrimoxazole (trimethoprim-
sulfamethoxazole) and also 
exhibits intermediate 
resistance to 
fluoroquinolones.  Carries 
arsenic resistance. 
patient in 1989 in Edinburgh. 
UK index case of the ET12 
lineage.  
Campylobacter jejuni 
RM1221 
Carries a four gene arsenic 
resistance cluster. Resistant 
to cephalosporins, β-lactams 
and sulphonamides 
Originally isolated from a 
chicken carcass.  
Wang et al., 2009; Fouts et 
al., 2005 
Klebsiella pneumoniae  
DA15000  
Plasmid pUUH239.2:   
A CTX-M-15-encoding 
multiresistance plasmid.  It 
confers resistance to: beta-
lactams, aminoglycosides, 
tetracyclines, trimethoprim, 
sulphonamides, quaternary 
ammonium ions, macrolides, 
silver, copper, and arsenic. 
Klebsiella pneumoniae strain 
involved in a large 
nosocomial outbreak in 
Uppsala University Hospital 
between 2005-2011.   
Sandegren et al., 2012 
Listeria monocytogenes 
serotype 4b 
Serotype 4b strains contain a 
35kb genomic island 
containing arsenic and 
Isolated in 1983 from a 
foodborne listeriosis 
outbreak. The Scott  A strain 
Briers et al., 2011; Lee et al., 
2013, 2014 
cadmium resistance.  is widely used as a reference 
strain 
Salmonella enterica serovar 
Typhimurium 
Plasmid R64.  Resistance to 
streptomycin, tetracycline 
and arsenic. 
Inc I group plasmid, isolated 
in the 1960s. 
Sampei et al., 2010 
Serratia marcescens Plasmid R478. Also confers 
resistance to tetracycline, 
chloramphenicol, kanamycin, 
mercury, copper, and 
tellurite. 
IncHI-2 group plasmid 
isolated in USA in 1969. 
Gilmour et al., 2004 
Staphylococcus aureus clonal 
complex 130 
30kb SCCmec element 
carrying  mecA, blaZ , and 
arsenic resistance 
Isolated in 2010 in Ireland Shore et al., 2011 
Staphylococcus capitis 
NRCSA strain CR01 
Novel 60.9kb composite 
staphylococcal cassette 
chromosome mec (SCCmec) 
methicillin resistance and an 
SCCcad/ars/cop carrying 
arsenic copper and cadmium 
resistance 
Isolated in 2007 in France 
from an infant with late onset 
sepsis in a neonatal Intensive 
Care Unit. 
Martins-Simoes et al., 2013 
Staphylococcus haemolyticus 
SH32 
28kb SCCmec (SH32) 
carrying the methicillin 
Isolated in 2003 in China 
from the blood of inpatient in 
Yu et al., 2014 
resistance  mec gene 
complex, arsenic, and copper 
resistance  
a hospital 
Staphylococcus 
pseudointermedius CC45 
Carries a novel SCCmec
57395
 
element. Resistance to 
oxacillin and penicillin, 
chloramphenicol, tetracycline, 
kanamycin, gentamicin, 
streptomycin, erythromycin, 
clindamycin, ciprofloxacin 
and arsenic, cadmium and 
copper resistance 
Methicillin resistant 
Staphylococcus 
pseudointermedius are an 
emerging problem in animal 
healthcare and can cause 
severe infections in humans 
Perreten et al., 2013 
Stenotrophomonas 
maltophila SM777 
Carries resistance to 
cadmium, lead, cobalt, zinc, 
mercury, silver, selenite, 
tellurite, uranium. 
Increasingly important as a 
nosocomial pathogen of 
cystic fibrosis patients and 
the immunocompromised. 
Pages et al., 2008 ; 
Crossman et al., 2008 
Yersinia enterocolitica Arsenic resistance carried on 
the 70kb pYV virulence 
plasmid.  
Tn2502 confers resistance to 
arsenite and arsenate. 
Neyt et al., 1997 
Yersinia Pestis JAVA 9 Carries 4 plasmids each of 
which carries Tn2503 
encoding arsenic resistance 
Isolated in 1957 in Java from 
a dead rat. The strain is fully 
virulent in non-human 
Eppinger et al., 2012 
related to Tn2502 carried on 
Yersinia enterocolitica pYV 
virulence plasmid. 
primate and rodent models, 
but lacks the Y. pestis-
specific plasmid pMT.  
 
Table 4: Arsenic resistance in recently sequenced strains. 
 
 
 
 
